Terns Pharmaceuticals Inc (TERN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Terns Pharmaceuticals Inc (TERN) has a cash flow conversion efficiency ratio of -0.070x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.77 Million) by net assets ($284.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Terns Pharmaceuticals Inc (TERN) liquidity interval to measure how many days the company can operate on defensive assets alone.
Terns Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Terns Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Terns Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Terns Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Veracruz Properties SOCIMI SA
MC:YVCP
|
0.025x |
|
Putra Mandiri Jembar Tbk PT
JK:PMJS
|
0.030x |
|
Hanjin Heavy Ind & Const Holdings Co Ltd
KO:003480
|
0.039x |
|
KNH Enterprise Co Ltd
TW:9919
|
-0.038x |
|
Baoye Group Company Limited
F:BKG
|
0.006x |
|
AXON PARTNERS GRP EO -10
F:XE1
|
N/A |
|
Talga Group Ltd
F:TGX
|
-0.234x |
|
Shotspotter Inc
NASDAQ:SSTI
|
0.062x |
Annual Cash Flow Conversion Efficiency for Terns Pharmaceuticals Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Terns Pharmaceuticals Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see TERN market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $345.87 Million | $-70.02 Million | -0.202x | +23.29% |
| 2023-12-31 | $255.37 Million | $-67.39 Million | -0.264x | -48.82% |
| 2022-12-31 | $276.94 Million | $-49.11 Million | -0.177x | +32.04% |
| 2021-12-31 | $160.30 Million | $-41.83 Million | -0.261x | +39.96% |
| 2020-12-31 | $68.59 Million | $-29.81 Million | -0.435x | +87.97% |
| 2019-12-31 | $18.32 Million | $-66.22 Million | -3.614x | -1344.50% |
| 2018-12-31 | $72.23 Million | $-18.07 Million | -0.250x | -- |
About Terns Pharmaceuticals Inc
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hor… Read more